Home/Filings/4/0001683168-21-001692
4//SEC Filing

Ruden Brian 4

Accession 0001683168-21-001692

CIK 0001622879other

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 9:39 PM ET

Size

23.9 KB

Accession

0001683168-21-001692

Insider Transaction Report

Form 4
Period: 2020-10-01
Ruden Brian
Director
Transactions
  • Award

    Series A Cumulative Convertible Preferred Stock

    2020-12-18$1000.00/sh+1,370$1,370,0002,801 total
    Exercise: $1.20Common Stock (1,141,667 underlying)
  • Award

    Series A Cumulative Convertible Preferred Stock

    2021-03-02$1000.00/sh+5,746$5,746,0009,151 total
    Exercise: $1.20Common Stock (4,788,333 underlying)
  • Award

    Warrant (Right to Buy)

    2020-12-17+268,375268,375 total
    Exercise: $1.20From: 2020-12-17Exp: 2025-12-17Common Stock (268,375 underlying)
  • Award

    Warrant (Right to Buy)

    2021-02-03+113,211113,211 total
    Exercise: $1.20From: 2021-02-03Exp: 2026-02-03Common Stock (113,211 underlying)
  • Award

    Common Stock

    2020-10-01+42,73542,735 total
  • Award

    Series A Cumulative Convertible Preferred Stock

    2020-12-17$1000.00/sh+1,431$1,431,0001,431 total
    Exercise: $1.20Common Stock (1,192,500 underlying)
  • Award

    Series A Cumulative Convertible Preferred Stock

    2021-02-03$1000.00/sh+604$604,0003,405 total
    Exercise: $1.20Common Stock (503,333 underlying)
  • Award

    Warrant (Right to Buy)

    2020-12-18+257,036257,036 total
    Exercise: $1.20From: 2020-12-18Exp: 2025-12-18Common Stock (257,036 underlying)
  • Award

    Warrant (Right to Buy)

    2021-03-02+1,077,3311,077,331 total
    Exercise: $1.20From: 2021-03-02Exp: 2026-03-02Common Stock (1,077,331 underlying)
Footnotes (5)
  • [F1]The issuer granted the reporting person shares of common stock with an aggregate value of $50,000 for service on its board of directors.
  • [F2]Subject to adjustment, as described in the Certificate of Designation.
  • [F3]The shares of Series A Cumulative Convertible Preferred Stock (the "Series A Preferred Shares") are convertible into shares of the common stock (the "Common Shares") of Medicine Man Technologies, Inc. (the "Company") upon the events specified in the Company's Certificate of Designation of Series A Cumulative Convertible Preferred Stock (the "Certificate of Designation"). The Preferred stock is perpetual and therefore has no expiration date.
  • [F4]Represents the number of Common Shares issuable upon conversion of the Series A Preferred Shares on the date of the reported transaction. Each Series A Preferred Share is convertible into that number of Common Shares equal to the preference amount (initially $1,000) plus any accrued dividends with respect to such share, divided by the conversion price (initially $1.20), subject to adjustment as set forth in the Certificate of Designation. The Series A Preferred Shares earn a cumulative dividend of 8% per annum.
  • [F5]The reporting person received the warrants under Asset Purchase Agreements entered into by entities partly-owned by the reporting person upon the sale of assets by such entities to the issuer on the following dates, December 17, 2020; December 18, 2020; February 3, 2021; March 2, 2021. The consideration paid for the assets consisted of a mix of cash, deferred cash, shares of the issuer's Series A Cumulative Convertible Preferred Stock (the "Series A Shares") and warrants to purchase shares of the issuer's common stock

Documents

1 file

Issuer

Medicine Man Technologies, Inc.

CIK 0001622879

Entity typeother

Related Parties

1
  • filerCIK 0001798268

Filing Metadata

Form type
4
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 9:39 PM ET
Size
23.9 KB